brain cancer

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News

France agrees to fund experimental glioblastoma therapy

France has agreed to provide temporary funding to help a clinical trial of an experimental therapy for glioblastoma, a notoriously hard-to-treat form of brain cancer, to go ahead.

News

Dr Elias Sayour, Chong Zhao and Arnav Barpujari discuss the mRNA cancer vaccine developed at the University of Florida

RNA glioblastoma vaccine shows promise in first human trial

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.

News

NICE backs Novartis duo for NHS use in young glioma patients

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use

News

ASCO: Vorasidenib shows its glioma potential in INDIGO

Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t

News